Company* (Symbol)**




Status (Date)***

Agouron Pharmaceuticals Inc. (a subsidiary of Warner-Lambert Co.; NYSE:WLA)

Prinomastat (formerly AG3340)

Matrix metalloprotease inhibitor

Advanced non-smallcell lung cancer

Initiated second Phase III trial in combination with chemotherapy (8/19)

Aronex Pharmaceuticals Inc. (ARNX)


Liposomal formulation of all trans-retinoic acid

Hormone-refractory metastatic prostate cancer

Expanded enrollment in Phase II trial (8/18)

Celgene Corp. (CELG) and National Cancer Institute


Thalidomide; thought to act by modulating levels of tumor necrosis factor-alpha

Colorectal cancer

Initiated Phase II trial (8/5)

Cell Pathways Inc. (CLPA)


Pro-apoptotic, anti-cancer

Various cancers compound

Reported completion of Phase Ia trial (8/4)

ImClone Systems Inc. (IMCL)


Monoclonal antibody, an inhibitor of the epidermal growth factor receptor associated with cancer cell growth in a number of solid tumors

Refractory advanced squamous cell head and neck cancer

Commencemed multi-center Phase II trial in combination with cisplatin (8/11)

The Liposome Company Inc. (LIPO)

Evacet (formerly TLC D-99)

Proprietary liposomal formulation of doxorubicin

Metastatic or locally advanced breast cancer

Commenced clinical trial in combination with the monoclonal antibody Herceptin (8/4)

The Liposome Company Inc. (LIPO) and RhonePoulenc Rorer Pharmaceuticals Inc. (NYSE:RP)

Evacet(formerly TLC D-99)

Proprietary liposomal formulation of doxorubicin

Metastatic breast cancer

Initiated clinical trial in combination with Taxotere (docetaxel) (8/11)

The Liposome Company Inc. (LIPO) and Bristol-Myers Squibb Co. (NYSE:BMY)

Evacet (formerly TLC D-99)

Proprietary liposomal formulation of doxorubicin

Metastatic breast cancer

Commenced clinical trial collaboration in combination with Taxol (paclitaxel) (8/25)

Matrix Pharmaceutical Inc. (MATX)

IntraDose Injectable Gel

Biodegradable gel combining cisplatin and epinephrine (intratumoral injection)

Metastatic liver cancer

Completed enrollment in Phase II trial (8/9)

Maxim Pharmaceuticals (AMEX:MMP; SSE: MAXM)

Maxamine therapy

H2 receptor agonist; combination therapy with low-dose interleukin-2

Acute myelogenous leukemia

Reported results of clinical trial (8/31)

Procept Inc. (NASDAQ SC: PRCT)


Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents

Breast cancer

Initiated Phase I trial (8/23)


Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents

Cutaneous T-cell lymphoma

Initiated Phase I trial (8/23)


Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents

Treatment of children with primary central nervous system tumors refractory to standard therapy

Initiated Phase I trial (8/23)


Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents

Patients with a variety of surgically resectable solid tumors

Initiated Phase I trial (8/23)

Protein Design Labs Inc. (PDLI)

SMART (humanized) 1D10 antibody

Humanized monoclonal antibody that binds to an HLA-DR determinant found on many pre-B and B-cell lymphomas

Patients with relapsed non-Hodgkin's lymphoma

Initiated Phase I trial (8/3)

Ribozyme Pharmaceuticals Inc. (RZYM)


Chemically synthesized ribozyme therapeutic; inhibits formation of vascular endothelial growth factor receptor (VEGF-r)


Reported results of Phase Ia and Ib trials (8/11)

Techniclone Corp. (TCLN)

Cotara (formerly TNT)

Tumor necrosis therapy; chimeric monoclonal antibody that targets DNA-associated histone antigens, labeled with I-131 (targets necrotic center of tumor)

Malignant glioma

Expanded Phase II trial (8/11)


Centocor Inc. (CNTO) and Eli Lilly and Co. (NYSE:LLY)

ReoPro (FDA-approved)

Chimeric monoclonal antibody fragment GPIIb/IIIa platelet receptor (abciximab)

Heart attack

Reported findings from international clinical trial (8/30)

CV Therapeutics Inc. (CVTX)


Perzine acetamide

Stable angina

Reported initial results from Phase III MARISA (monotherapy assessment of Ranolazine in stable angina) trial (8/18)

Discovery Therapeutics Inc.*


A selective adenosine A1 agonist

Paroxysmal supra-ventricular tachycardia; tachcardia associated with atrial fibrillation

Initiated Phase I trial (8/31)

Emisphere Technologies Inc. (EMIS)

Oral formulation of heparin

Prevention of venous thromboembolic events following elective hip arthroplasty

Reported results of Phase II trial at the XVIIth Congress of the International Society of Thrombosis and Haemostasis (8/19)

Interneuron Pharmaceuticals Inc. (IPIC)


Citocholine sodium; organic molecule that consists of cytidine and choline (components of brain cell membranes)

Ischemic stroke

Completed enrollment in Phase III trial (8/26)

Pharmacyclics Inc. (PCYC)


Water-soluble photosensitizer that accumulates in atherosclerosis, is cleared rapidly from the blood and is activated by 732 nm

Photoangioplasty in patients with symptomatic peripheral arterial disease light; drug is intravenously delivered

Reported results from Phase I trial (8/30)

United Therapeutics Corp. (UTHR)


Modified version of prostacyclin molecule

Primary pulmonary hypertension

Presented results of comparison study at the European Society of Cardiology convention (8/31)


Guilford Pharmaceuticals Inc. (GLFD) and Amgen Inc. (AMGN)

Class of compounds known as neuroimmunophilins

Parkinson's disease

Initiated Phase I trial (8/14)


Amylin Pharmaceuticals Inc. (AMLN)

Symlin (pramlintide acetate)

Synthetic analogue of the hormone amylin

Type 2 diabetes

Reported results of Phase III trial (8/31)

Generex Biotechnology Corp. (OTC BB: GNBT)

Bucally administered insulin

Post-prandial hyper-glycemia

Reported completion of Phase II trials (8/10)

Genzyme Tissue Repair (GZTR)


Protein that promotes normal wound healing by stimulating connective tissue growth

Diabetic foot ulcers

Reported completion of Phase II trial (8/31)

Organogenesis Inc. (AMEX:ORG)

Apligraf (FDA-approved)

Living human skin equivalent, composed of living human keratinocytes and fibroblasts (epidermis and dermis, isolated from infant foreskins) cultured in a 3-dimensional system

Diabetic foot ulcers

Reported results of pivotal trial (8/25)


Avant Immunotherapeutics (AVAN) and Pasteur Merieux Connaught

Adjumer-formulated vaccine

Respiratory syncytial virus

Initiated Phase I trial (8/23)

Aviron (AVIR)

Vaccine based on the single surface antigen responsible for most of the neutralizing anti- bodies stimulated by Epstein-Barr virus

Epstein-Barr virus

Reported results of Phase I trial (8/11)

BioCryst Pharmceuticals Inc. (BCRX) and R.W. Johnson Pharmaceutical Research Institute (a unit of Johnson & Johnson; NYSE: JNJ)


Neuraminidase inhibitor

Influenza A

Reported preliminary Phase II results (8/24)

Chiron Corp. (CHIR)

Proleukin (aldesleukin)

Recombinant form of T-cell growth factor (interleukin-2)

HIV patients with low CD4+ T-cell counts

Commenced patient enrollment in Phase III trial (8/18)

Nabi (NABI)


Capsular polysaccharide conjugate vaccine for Staphylococcus aureus infections

Treatment of S. aureus infections in hemodialysis patients

Reported positive interim results from pivotal trial (8/25)


Alexion Pharmaceuticals Inc. (ALXN)


Anti-inflammatory complement inhibitor

Rheumatoid arthritis

Initiated Phase II trial (8/4)


Anti-inflammatory complement inhibitor

Membranous nephritis

Initiated Phase II trial (8/11)

Anika Therapeutics Inc. (ANIK)


High molecular weight, naturally derived form of hyaluronic acid

Osteoarthritis of the knee

Completed patient enrollment in Phase III trial (8/19)

Bayer Corp.*


Recombinant version of a naturally occurring coagulation protein

Hemophilia A

Reported results from two clinical trials (8/18)

BioSpecifics Technologies Corp. (BSTC)


Injectable collagenase enzyme

Peyronie's disease

Reported positive preliminary results of clinical trial (8/9)

Bio-Technology General Corp. (BTGC)


High molecular weight sodium

Osteoarthritis of the knee hyaluronate injection

Initiated efficacy study (8/30)

CytRx Corp. (CYTR)


Purified poloxamer 188; intravenously delivered surfactant molecule that alters the way cells and molecules interact with water

Acute lung injury

Initiated Phase I/II study (8/30)

Discovery Laboratories Inc. (NASDAQ SC: DSCO)

SuperVent Aerosol Solution

Tyloxapol (non-anionic alkylaryl and polyether alcohol)

Cystic fibrosis

Initiated Phase IIa trial

Duramed Pharmaceuticals Inc. (DRMD)

Cenestin tablets

Plant-derived (soy and yams) synthetic complex mixture conjugated estrogens product

Moderate-to-severe vasomotor symptoms associated with menopause

Completed bioequivalence study (8/4)

Dynavax Technologies Corp.*

Amb a 1 Immunostimulatory Conjugate (AIC)

Therapeutic conjugate that induces an enhanced Amb a 1-specific, Th1-type response

Allergic rhinitis

Reported completion of patient enrollment and dosing in Phase I trial (8/19)

Eli Lilly & Co. (NYSE:LLY)

Olanzapine (Zyprexa)

Selective monoaminergic antagonist belonging to the thienobenzodiazepine class of antipsychotics

Hyperprolactinemia in schizophrenia patients

Reported results of clinical study (8/2)

Immunex Corp. (IMNX)

Enbrel (FDA-approved)

Etanercept; recombinant, soluble T75 tumor necrosis factor (TNFr) linked to the Fc portion of human IgG1

Psoriatic arthritis

Reported clinical trial results (8/16)

IntraBiotics Pharmaceuticals Inc.*

Protegrin IB-367

Synthetic analogue of protegrin family of mammalian antimicrobial peptides (liquid formulation delivered via nebulizer)

Oral mucositis

Reported completion of Phase II trial (8/10)

Iomed (AMEX:IOX)


Dexamethasone sodium phosphate

Acute local inflammatory conditions

Initiated Phase III trial (8/11)

MacroChem Corp. (MCHM)


1% alprostadil and 5%

Erectile dysfunction Sepa topical formulation

Reported completion of series of clinical trials (8/4)

NexMed Inc. (OTC BB:NEXM)


Proprietary topical formulation combining NexMed's NexACT penetration drug delivery technology with alprostadil

Female sexual dysfunction

Reported Phase I trial results (8/6)


* Indicates a privately held company

** Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

*** The dates listed indicate the issue dates of press releases.